GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kintara Therapeutics Inc (STU:3DMA) » Definitions » Net Margin %

Kintara Therapeutics (STU:3DMA) Net Margin % : 0.00% (As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Kintara Therapeutics Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Kintara Therapeutics's Net Income for the three months ended in Jun. 2024 was €-2.16 Mil. Kintara Therapeutics's Revenue for the three months ended in Jun. 2024 was €0.00 Mil. Therefore, Kintara Therapeutics's net margin for the quarter that ended in Jun. 2024 was 0.00%.

The historical rank and industry rank for Kintara Therapeutics's Net Margin % or its related term are showing as below:


STU:3DMA's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -139.77
* Ranked among companies with meaningful Net Margin % only.

Kintara Therapeutics Net Margin % Historical Data

The historical data trend for Kintara Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kintara Therapeutics Net Margin % Chart

Kintara Therapeutics Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Kintara Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Kintara Therapeutics's Net Margin %

For the Biotechnology subindustry, Kintara Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kintara Therapeutics's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kintara Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Kintara Therapeutics's Net Margin % falls into.



Kintara Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Kintara Therapeutics's Net Margin for the fiscal year that ended in Jun. 2024 is calculated as

Net Margin=Net Income (A: Jun. 2024 )/Revenue (A: Jun. 2024 )
=-7.729/0
= %

Kintara Therapeutics's Net Margin for the quarter that ended in Jun. 2024 is calculated as

Net Margin=Net Income (Q: Jun. 2024 )/Revenue (Q: Jun. 2024 )
=-2.159/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kintara Therapeutics  (STU:3DMA) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Kintara Therapeutics Net Margin % Related Terms

Thank you for viewing the detailed overview of Kintara Therapeutics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Kintara Therapeutics Business Description

Traded in Other Exchanges
Address
9920 Pacific Heights Boulevard, Suite 150, San Diego, CA, USA, 92121
Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.

Kintara Therapeutics Headlines

No Headlines